The Brigham and Dana-Farber Board Review and Comprehensive Update in Oncology 2022 (Videos+PDFs)

The Brigham and Dana-Farber Board Review and Comprehensive Update in Oncology 2022 

Board Review Video Series

Product Details

---

Download Link:

This post contains protected content. You must be logged in and have 1800 points to unlock it.

---

Description:

Key Topics in Oncology CME

The Brigham and Dana-Farber Board Review and Comprehensive Update in Oncology is an online CME course designed to update knowledge and improve management strategies. This collection of case-based presentations — presented by a distinguished faculty of experts — will help enhance patient care while you prep for your board exam. It’s continuing medical education that helps you to:

• Apply recommended oncology guidelines in clinical practice
• Perform differential diagnosis of complex oncologic disorders
• Identify and apply current therapeutic options for oncologic disorders
• Evaluate and interpret up-to-date literature relevant to oncology
• Illustrate knowledge of pathophysiology as it applies to management of oncology disorders
• Apply knowledge gained to the ABIM certification/recertification oncology examinations

Accreditation

Oakstone Publishing is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

Oakstone Publishing designates this enduring material for a maximum of 29 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Successful completion of this CME activity enables the participant to earn up to 29 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Date of Original Release: July 15, 2022
Termination Date: July 15, 2025

Learning Objectives

At the conclusion of this activity, the participant will be able to:

• Apply current/recommended oncology guidelines in clinical practice
• Perform differential diagnosis of complex clinical presentations related to oncologic disorders
• Identify/apply current therapeutic options for specific oncologic disorders
• Review and interpret up-to-date literature relevant to clinical practice in oncology
• Demonstrate knowledge of pathophysiology as it applies to management of oncology disorders
• Apply knowledge gained to the ABIM certification/recertification oncology examinations

Intended Audience

The activity was planned for fellows/trainees, practicing oncology specialists (MDs), and other professional affiliates (internists with an interest in oncology) who are preparing to take ABIM board review or recertification examinations, or who seek CME activities to improve patient care in the areas of medical oncology.

Topics/Speaker:

Molecular Genetics of Cancer – Nikhil Wagle, MD

Advances in Cancer Drug Development Part I – Chemotherapy and Targeted Agents – Geoffrey I. Shapiro, MD, PhD

Advances in Cancer Drug Development Part II – Modulation of the Tumor Microenvironment – Geoffrey I. Shapiro, MD, PhD

Infections in Cancer Patients – Lindsey Baden, MD

Symptom Management in Patients with Cancer – Andrew J. Lawton, MD

Communication: The Key to Excellence in End-of-Life Care – Rachelle E. Bernacki, MD, MS, FAAHPM, AGSF

Biology of Hematopoietic Stem Cell Transplantation – Robert J. Soiffer, MD

Biology of Acute Leukemia and Myelodysplastic Syndromes – Benjamin L. Ebert, MD, PhD

Acute Leukemias – Daniel J. DeAngelo, MD, PhD

Myelodysplastic Syndrome – Eric S. Winer, MD

Chronic Myelogenous Leukemia – Marlise R. Luskin, MD

Myeloproliferative Syndromes – Ann M. Mullally, MD

Multiple Myeloma – Kenneth C. Anderson, MD

Waldenstrom Macroglobulemia and Amyloidosis – Jorge J. Castillo, MD

Low Grade Lymphomas – Caron A. Jacobson, MD

Aggressive Non-Hodgkin Lymphoma – Eric D. Jacobsen, MD

Hodgkin’s Lymphoma – Reid W. Merryman, MD

Diagnosis and Treatment of CLL and Related B Cell Malignancies – Matthew S. Davids, MD

Head and Neck Cancer – Robert I. Haddad, MD

Natural History, Screening, and Small Cell Lung Cancer – Bruce E. Johnson, MD

Management of Stage I-III Non Small Cell Lung Cancer – Part 1 – Mark Awad, MD, PhD

Management of Metastatic Non Small Cell Lung Cancer – Part 2 – Mark Awad, MD, PhD

Mesothelioma and Thymoma – David M. Jackman, MD

Carcinoid and Neuroendocrine Tumors – Jennifer Ang Chan, MD

Novel Approaches for the Management of Esophageal and Gastric Cancers – Peter C. Enzinger, MD

Pancreatic Cancer – Brian M. Wolpin, MD

Hepatobiliary Cancer – James M. Cleary, MD, PhD

Anal Cancer & Colorectal Cancers Part 1 – Robert J. Mayer, MD

Colorectal Cancers Part 2 – Robert J. Mayer, MD

Gastrointestinal Cancer: Genetic Syndromes – Matthew Yurgelun, MD

Testicular Cancer – Mark M. Pomerantz, MD

Renal and Bladder Cancer – Guru P. Sonpavde, MBBS

Prostate Cancer Part I: Overview and Management of Localized Disease – Atish D. Choudhury, MD, PhD

Prostate Cancer Part II: Management of Disseminated Prostate Cancer – Atish D. Choudhury, MD, PhD

Melanoma – F. Stephen Hodi, MD

Sarcomas and Gastrointestinal Stromal Tumors (GIST) – Suzanne George, MD

Molecular Advances and Emerging Treatment Strategies in Ovarian Cancer – Ursula A. Matulonis, MD

Cervical and Endometrial Cancer – Panagiotis A. Konstantinopoulos, MD, PhD

Neuro-oncology – David A. Reardon, MD

Breast Cancer – Risk Factors, Genetics, Screening, and Prevention – Judy E. Garber, MD, MPH

Multimodality Therapy for Early Stage Breast Cancer: Part 1 – Surgery and Radiation – Harold J. Burstein, MD, PhD

Multimodality Therapy for Early Stage Breast Cancer: Part 2 – Systemic Therapy – Harold J. Burstein, MD, PhD

Management of Metastatic Breast Cancer – Adrienne G. Waks, MD

Breast Cancer Survivorship – Ann H. Partridge, MD, MPH